ClinVar Miner

Submissions for variant NM_000303.3(PMM2):c.385G>A (p.Val129Met)

dbSNP: rs104894525
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000008147 SCV000220186 likely pathogenic PMM2-congenital disorder of glycosylation 2014-03-23 criteria provided, single submitter literature only
GeneDx RCV000344673 SCV000329702 pathogenic not provided 2022-01-27 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect with a decease in the activity and stability of the protein (Pirard et al., 1999); Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30577886, 32630370, 25525159, 9140401, 18629883, 31981409, 11409861, 34426522, 33643843, 10386614)
Eurofins Ntd Llc (ga) RCV000344673 SCV000331816 pathogenic not provided 2018-04-24 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000008147 SCV000696496 pathogenic PMM2-congenital disorder of glycosylation 2017-02-23 criteria provided, single submitter clinical testing Variant summary: The PMM2 c.385G>A (p.Val129Met) variant located in the HAD-like domain (via InterPro) involves the alteration of a conserved nucleotide, which 3/4 in silico tools (SNPs&GO not captured due to low reliability index) predict a damaging outcome. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 1/31420, which does not exceed the estimated maximal expected allele frequency for a pathogenic PMM2 variant of 1/178. Multiple publications have cited the variant in affected individuals presenting with both severe and mild phenotypes dependent upon the PMM2 variant in trans. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic. Taken together, this variant is classified as pathogenic.
SIB Swiss Institute of Bioinformatics RCV000008147 SCV000803499 likely pathogenic PMM2-congenital disorder of glycosylation 2018-05-31 criteria provided, single submitter curation This variant is interpreted as a Likely Pathogenic, for Congenital disorder of glycosylation, type Ia, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:11058896). PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PS3-Moderate => PS3 downgraded in strength to Moderate (PMID:10386614).
Invitae RCV000008147 SCV001215077 pathogenic PMM2-congenital disorder of glycosylation 2023-11-15 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 129 of the PMM2 protein (p.Val129Met). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with congenital disorder of glycosylation type 1a (CDG1a) (PMID: 9140401, 18629883, 18948042). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 7708). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PMM2 protein function. This variant disrupts the p.Val129 amino acid residue in PMM2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16941129). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics, Fulgent Genetics RCV000008147 SCV002775184 pathogenic PMM2-congenital disorder of glycosylation 2022-01-09 criteria provided, single submitter clinical testing
Baylor Genetics RCV000008147 SCV004205299 pathogenic PMM2-congenital disorder of glycosylation 2023-02-24 criteria provided, single submitter clinical testing
OMIM RCV000008147 SCV000028352 pathogenic PMM2-congenital disorder of glycosylation 1997-05-01 no assertion criteria provided literature only
Pediatric Metabolic Diseases, Hacettepe University RCV000008147 SCV000998571 likely pathogenic PMM2-congenital disorder of glycosylation no assertion criteria provided clinical testing
Natera, Inc. RCV000008147 SCV002089478 pathogenic PMM2-congenital disorder of glycosylation 2020-10-22 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.